View clinical trials related to Second-line Treatment.
Filter by:This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
This prospective, unicentric, open-labe phase I study is to evaluate the safety and effect of autologous cytotoxic T lymphocyte immunotherapy combination with PD-1 inhibitor in the second-line treatment of stage IIIB/IIIC/IV non-small cell lung cancer.